Status and phase
Conditions
Treatments
About
The primary objective of this study is to investigate the efficacy of Ingavirin®, 90 mg capsules in achieving clinical improvement of novel coronavirus disease (COVID-19) symptoms. A secondary goal of this study is to evaluate the safety of Ingavirin®, 90 mg capsules in patients with COVID-19 infection.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Withdrawal Criteria:
Primary purpose
Allocation
Interventional model
Masking
233 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal